Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.52 |
| ▸ | HTR3B | O95264 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046640 | 0.93 | IGF1R (0.53) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15352562 | 0.91 | IGF1R (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15352211 | 0.91 | IGF1R (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9238570 | 0.91 | IGF1R (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15352069 | 0.91 | IGF1R (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1047259 | 0.91 | IGF1R (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3890912 | 0.91 | IGF1R (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL11146715 | 0.91 | IGF1R (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9653036 | 0.91 | IGF1R (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL11353612 | 0.91 | IGF1R (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569908-B1 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2010-09-15 | — | — | EP | claimed |
| US-7405230-B2 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-29 | — | — | US | claimed |
| US-7087625-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| EP-1569908-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | claimed |
| WO-2004046113-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| EP-1121118-A4 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LTD (GB) | 2002-09-11 | — | — | EP | claimed |
| EP-1121118-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2001-08-08 | — | — | EP | claimed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | claimed |
| WO-2000012083-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-20230018615-A1 | STEROIDS AND METHODS OF MANUFACTURE | TRUSTEES OF DARTMOUTH COLLEGE | 2023-01-19 | — | — | US | disclosed |
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-08-19 | — | — | US | disclosed |
| EP-3178323-B1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-4301164-A | FOR USE AS ANTIULCER AGENTS, HYPOTENSIVE AGENTS, ANTITHROMBOSIC AGENTS | TORAY INDUSTRIES, INC. (JP) | 1981-11-17 | — | — | US | disclosed |
| EP-0024943-A1 | 5,6,7-Trinor-4,8-inter-m-phenylene PGI2 derivatives and pharmaceutical compositions containing them | TORAY INDUSTRIES, INC. (JP) | 1981-03-11 | — | — | EP | disclosed |
| US-4053478-A | ARTERIOSCLEROSIS, THROMBOSIS, HYPERTENSION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1977-10-11 | — | — | US | disclosed |
| US-4012412-A | USEFUL IN THE TREATMENT OF HYPERTENSION, ARTERIOSCLEROSIS, AND THROMBOSIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1977-03-15 | — | — | US | disclosed |
| US-3998827-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018615-A1 | STEROIDS AND METHODS OF MANUFACTURE | HSD17B7, HSD11B1, HSD11B2 | TAAR1 1654/4885HTR3E 2715/4885HTR3B 2246/4885 |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP1A2 | TAAR1 3292/4885HTR3E 3322/4885HTR3B 2881/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | TAAR1 278/4885HTR3E 525/4885HTR3B 241/4885 |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | TAAR1 525/4885HTR3E 826/4885HTR3B 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.